1. Baurain, R, Deprez-De Campaneere, D & Trouet, A (1979). Rapid determination of doxorubicin and its fluorescent metabolites by high pressure liquid chromatography. Anal Biochem 94: 112–116.
2. Bosslet, K, Straub, R, Blumrich, M, Czech, J, Gerken, M, Sperker, B, Kroemer, HK, Gesson, JP, Koch, M & Monneret, C (1998). Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 58: 1195–1201.
3. Connors, TA & Whisson, ME (1966). Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature 210: 866–867.
4. Duncan, R, Coatsworth, JK & Burtles, S (1998). Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1). Human Exp Toxicol 17: 93–104.
5. Florent, JC, Gaudel, G, Mitaku, S, Monneret, C, Gesson, JP, Jacquesy, JC, Mondon, J, Martine, C, Renoux, B, Adrianomenjanahary, S, Michel, S, Koch, M, Tillequin, F, Gerken, M, Czech, J, Straub, R & Bosslet, K (1998). Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J Med Chem 41: 3572–3581.